Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.
Thesis pillars
- Strong Revenue Growth→Stable
- Overbought Late Cycle Risk↓Deteriorating
- Notable Insider Selling↑Improving
- +2 more pillars — see the Why tab for full reasoning
Omada Health, Inc. (OMDA) Stock Analysis
Breakout setup
Healthcare · Health Information Services
Wait for pullback to $20.92. Insider activity concern; also weak momentum — blocks BUY_NOW at $24.35. Engine's entry $20.92 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Elevated risk factors.
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more
Wait for pullback to $20.92. Insider activity concern; also weak momentum — blocks BUY_NOW at $24.35. Engine's entry $20.92 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Elevated risk factors. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.9/10, moderate confidence.
Passes 6/9 gates (positive momentum, no SEC red flags, news boost analyst 0.40, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
Recent developments
updated 2026-08-14Recent Developments — Omada Health, Inc.
Latest news
- NEWS Omada Health CFO Steven Cook sells $421k in stock - Investing.com — Investing.com negative
- NEWS Omada Health (NASDAQ:OMDA) CFO Sells $381,332.05 in Stock - MarketBeat — MarketBeat negative
- NEWS Omada Health (OMDA) Could Be 4% Undervalued As Record Earnings Reset The Debate - Yahoo Finance — Yahoo Finance positive
- NEWS Omada Health (OMDA) Could Be 4% Undervalued As Record Earnings Reset The Debate - finance.yahoo.com — finance.yahoo.com positive
- NEWS Wall Street Zen Upgrades Omada Health (NASDAQ:OMDA) to Buy - MarketBeat — MarketBeat positive
Generated 2026-08-14T16:37:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerlimited number of customers and channel partners10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
- MEDIUMSupplierlimited number of third-party suppliers10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $20.92. Insider activity concern; also weak momentum — blocks BUY_NOW at $24.35. Engine's entry $20.92 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Elevated risk factors. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $24.67 (+1.3%), stop $18.15 (−34.2%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Take-profit target: $24.67 (-4.4% upside). Target $24.67 (+1.3%), stop $18.15 (−34.2%), A.R:R -0.3:1. Stop-loss: $18.15.
Analyst target reached - limited upside remaining; Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (41 sells, 0.38% of cap).
Omada Health, Inc. trades at a P/E of 35.8 (forward 45.9). TrendMatrix value score: 4.1/10. Verdict: Buy (Wait for Entry).
18 analysts cover OMDA with a consensus score of 4.0/5. Average price target: $27.
What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.